1 unchanged sentence
Trading arrangements
−Removed: During the three months ended March 31, 2026 , no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K).
+Added: During the three months ended June 30, 2026 , no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K) , except as follows:
+Added: On May 12, 2026 , Tommy DiRaimondo , Ph.D., our Chief Scientific Officer , adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 97,938 shares of our common stock until August 15, 2027.
+Added: On May 12, 2026 , Maria Dobek , our Vice President , Accounting, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 94,171 shares of our common stock until August 15, 2027.
+Added: In addition, our officers (as defined in Rule 16a-1(f) under the Exchange Act) have entered into sell-to-cover arrangements adopted pursuant to Rule 10b5-1 authorizing the pre-arranged sale of shares to satisfy our tax withholding obligations arising exclusively from the vesting of restricted stock units.
+Added: The amount of shares to be sold to satisfy our tax withholding obligations under these arrangements is dependent on future events which cannot be known at this time, including the future trading price of our shares.
+Added: The expiration date relating to these arrangements is dependent on future events which cannot be known at this time, including the final vesting date of the applicable shares of restricted stock and the officer’s termination of service.
Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed June 15, 2021).
5 unchanged sentences
Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed February 29, 2024).
−Removed: Amended and Restated Non-Employee Director Compensation Policy.
−Removed: Employment Agreement, by and between the Registrant and William Go, M.D., Ph.D., dated January 12, 2026.
−Removed: Exclusive License and Collaboration Agreement, by and between the Registrant and Bristol Myers Squibb, dated January 21, 2026.
Certification of Principal Executive and Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
4 unchanged sentences
Cover Page Interactive Data File (embedded within the Inline XBRL document)
−Removed: Indicates management contract or compensatory plan.
−Removed: Certain portions of this exhibit are omitted because they are not material and would likely cause competitive harm to the Registrant if disclosed.
The information in Exhibit 32.1 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report on Form 10-Q), unless the Registrant specifically incorporates the foregoing information into those documents by reference.
1 unchanged sentence
JANUX THERAPEUTICS, INC.
+Added: August 6, 2026
/s/ David Campbell, Ph.D.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.